| Compounds | Topics | Title | Date |
|---|---|---|---|
| Geraniol | cancer,breast cancer,lung cancer via review | The antitumor effects of geraniol: Modulation of cancer hallmark pathways (Review) | May 2016 |
| Geraniol is a dietary monoterpene alcohol that is found in the essential oils of aromatic plants. To date, experimental evidence supports the therapeutic or preventive effects of geraniol on different types of cancer, such as breast, lung, colon, prostate, pancreatic, and hepatic cancer, and has revealed the mechanistic basis for its pharmacological actions. | |||
| Geraniol | cancer,breast cancer in vitro | Geraniol and beta-ionone inhibit proliferation, cell cycle progression, and cyclin-dependent kinase 2 activity in MCF-7 breast cancer cells independent of effects on HMG-CoA reductase activity. | Nov 2004 |
| These findings indicate that mechanisms other than impaired mevalonate synthesis mediate the anti-proliferative and cell cycle regulatory effects of beta-ionone and geraniol in human breast cancer cells. | |||
| Geraniol | diabetes,neuropathy in rats via experiment | Protective effects of geraniol (a monoterpene) in a diabetic neuropathy rat model: Attenuation of behavioral impairments and biochemical perturbations | Sept 2014 |
|
Ingestion Method: 100 mg/kg bw/day From our data, we hypothesize that GE may be a promising therapeutic candidate in the management of DN in humans. | |||
| Geraniol | cancer,prostate cancer in vitro | Geraniol suppresses prostate cancer growth through down-regulation of E2F8. | Oct 2016 |
|
Action Pathway: E2F8 Geraniol potently altered a gene expression profile and primarily down-regulated cell cycle-related gene signatures, compared to linalool, another structurally similar monoterpene that induces no apparent phenotypic changes. Master regulator analysis using the prostate cancer-specific regulatory interactome identified that the transcription factor E2F8 as a specific target molecule regulates geraniol-specific cell cycle signatures. | |||
| Geraniol | diabetes in rats | Geraniol, a natural monoterpene, ameliorates hyperglycemia by attenuating the key enzymes of carbohydrate metabolism in streptozotocin-induced diabetic rats. | Dec 2017 |
|
Ingestion Method: 100, 200 and 400 mg/kg b.w. The present findings suggest that geraniol can potentially ameliorate key enzymes of glucose metabolism in experimental diabetes even though clinical studies used to evaluate this possibility are warranted. | |||
| Geraniol | anti-fungal in vitro | Geraniol interferes with membrane functions in strains ofCandida andSaccharomyces | Jun 1988 |
| Biophysical studies using differential scanning calorimetry, fluorescence polarization and osmotic swelling of phospholipid vesicles demonstrated that geraniol decreased the phase-transition temperature of dipalmitoylphosphatidylcholine vesicles, affected fluidity throughout the bilayer, particularly the central portion of the bilayers, and caused an increase in bilayer permeability to erythritol. Geraniol may have potential use as an antifungal agent. | |||
| Geraniol | sedative in rats via experiment | Depressant effect of geraniol on the central nervous system of rats: Behavior and ECoG power spectra. | Oct 2018 |
|
Ingestion Method: 25, 50 and 100 mg/kg intravenous Positive The results showed that geraniol treatment in rats decreased the distance traveled, rearing numbers and lead to increase in immobility time in HB and OF tests. In BIST test, geraniol treatment increased sleep duration but not sleep latency in the animals. Furthermore, geraniol-treated animals demonstrated an increase in the percentage of delta waves in the total spectrum power. Taken together, our results suggested that geraniol exerted a depressant effect on the central nervous system of rats. | |||